Palvella presents new QTORIN data at dermatology conference

what happened

GlobeNewswire reported that Palvella Therapeutics presented three posters at the 26th Annual Fall Clinical Dermatology Conference. The materials covered the Phase 3 SELVA study of QTORIN™ rapamycin in microcystic lymphatic malformations, systemic rapamycin exposure and the U.S. population diagnosed with DSAP.

At Week 24, every participant in the interview study reported improvement in at least one symptom, most often bleeding or leaking and color. Among participants who completed the efficacy evaluation period, 95% improved on the mLM-IGA endpoint, including 86% rated “Much Improved” or “Very Much Improved.” All participants who completed the TSQM-9 reported treatment satisfaction, while 98% continued into the Treatment Extension Period.

In the 24-person pharmacokinetic substudy, mean systemic rapamycin exposure was at least 40 times lower than reported exposure to oral sirolimus, with concentrations remaining low and stable over 24 hours. A Komodo Health claims analysis estimated 154,986 U.S. patients diagnosed with DSAP during 2018–2025. Palvella completed the rolling NDA submission to the FDA for QTORIN rapamycin in August 2026, while a Phase 2 trial of QTORIN pitavastatin in DSAP is expected to begin in the fourth quarter of 2026. Both candidates remain investigational and have not been approved by the FDA or any other regulatory agency.

why it matters

The update adds clinical, pharmacokinetic and epidemiological data to Palvella’s development story. Market attention is likely to focus on FDA review of QTORIN rapamycin and the planned Phase 2 start for QTORIN pitavastatin.

instruments